Page 4 - Adicet Bio News Today

Adicet Bio, Inc. , a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced the pricing of an...

Adicet Bio, Inc. , a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that it has commenced...

StockNews.com upgraded shares of Adicet Bio (NASDAQ:ACET – Free Report) to a sell rating in a research report released on Tuesday. Separately, Wedbush reissued an outperform rating and issued a $5.00 target price on shares of Adicet Bio in a report on Thursday, January 4th. One equities research analyst has rated the stock with a […]

StockNews.com upgraded shares of Adicet Bio (NASDAQ:ACET – Free Report) to a sell rating in a research report released on Tuesday. Separately, Wedbush reissued an outperform rating and issued a $5.00 target price on shares of Adicet Bio in a report on Thursday, January 4th. One equities research analyst has rated the stock with a […]

Adicet Bio, Inc. (NASDAQ:ACET – Free Report) – Stock analysts at Wedbush issued their FY2028 earnings per share (EPS) estimates for Adicet Bio in a research note issued to investors on Thursday, January 4th. Wedbush analyst R. Driscoll anticipates that the company will post earnings per share of ($1.16) for the year. Wedbush has a […]

Each week, Benzinga’s Stock Whisper Index uses a combination of proprietary data and pattern recognition to showcase five stocks that are just under the surface and warrant attention.

Shares of Mobileye Global Inc. (NASDAQ: MBLY) fell sharply during Thursday’s session after the company issued preliminary FY23 financial results and initial 2024 guidance.<

By Denny Jacob Adicet Bio shares surged 25%, to $2.21, following bullish commentary from the clinical stage biotechnology company on its outlook. The stock...

Adicet Bio, Inc. , a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced it granted an inducement award on December 29,...

ADI-001 showed robust dose-dependent expansion and persistence in patients with relapsed/refractory aggressive B-cell non-Hodgkin’s lymphoma (NHL)Strong exposure and persistence profile further supports Adicet’s allogeneic chimeric antigen receptor (CAR) T platform potential as best-in-classPharmacodynamic (PD) and...